Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics plc - American Depositary Shares
(NQ:
BCYC
)
6.825
+0.005 (+0.07%)
Streaming Delayed Price
Updated: 10:32 AM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Expert Ratings for Bicycle Therapeutics
↗
May 06, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
↗
May 05, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
↗
April 13, 2022
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics...
Via
Benzinga
Where Bicycle Therapeutics Stands With Analysts
↗
April 13, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
↗
April 13, 2022
Upgrades
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 11, 2022
Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.
Via
Benzinga
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 11, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
↗
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
↗
April 08, 2022
Via
Benzinga
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
↗
April 08, 2022
Early-stage testing shows promise for this biotech company's Covid antiviral.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
↗
April 08, 2022
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...
Via
Benzinga
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
April 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics's Return On Capital Employed Overview
↗
March 04, 2022
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
↗
March 03, 2022
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Bicycle Therapeutics: Q4 Earnings Insights
↗
March 01, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
↗
February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...
Via
Benzinga
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
January 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
↗
December 31, 2021
The list features stocks from diverse sectors as the economy recovers from the pandemic.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
↗
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
↗
December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:
Via
Benzinga
7 A-Rated Biotechs to Buy for the Long Run
↗
December 03, 2021
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
Via
InvestorPlace
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
November 09, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed
↗
November 08, 2021
According to Benzinga Pro data, during Q3, Bicycle Therapeutics (NASDAQ:BCYC) posted sales of $4.33 million. Earnings were up 17.27%, but Bicycle Therapeutics still reported an...
Via
Benzinga
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
